Speciality Medicines Key Ratios
BSE: 544738
₹141.80
₹-7.20
(-4.83%)
As on 23-Oct-2026IST
Market cap
₹125 Cr
Revenue (TTM)
₹75 Cr
P/E Ratio
9.6
P/B Ratio
1.7
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | 29.20 | 47.96 | -- |
| EBIT | -- | -- | 51.24 | 60.25 | -- |
| Net Profit | -- | -- | 81.11 | 97.61 | -- |
| EPS | -- | -- | 32.67 | 49.71 | -- |
| Book Value | -- | -- | 70.31 | 74.07 | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | Mar-26 | Mar-25 | Mar-24 |
| EBIT-Margin
| 17.19 | -- | 17.94 | 15.33 | 18.31 |
| Net Margin
| 13.34 | -- | 17.12 | 12.29 | 10.61 |
| Return on equity
| 28.38 | -- | 25.60 | 31.50 | 28.03 |
| Return on Capital
| 32.44 | -- | 25.26 | 34.34 | 37.72 |
| Return on Assets
| 19.54 | -- | 19.27 | 22.97 | 16.36 |
| Debt to Equity (x)
| -- | -- | 0.09 | 0.16 | 0.19 |
Profitability
ROCE
25.26
No difference
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
25.26
|
34.34
|
37.72
|
52.41
|
69.75
|
|
Peer Median
|
25.26
|
3.84
|
5.02
|
9.20
|
--
|
ROE
25.60
Higher than Peers by 3.91
Profit after tax / Average Net worth * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
25.60
|
31.50
|
28.03
|
43.30
|
76.56
|
|
Peer Median
|
21.69
|
5.08
|
1.59
|
9.09
|
--
|
ROA
19.27
Higher than Peers by 4.30
Profit after tax / Average Total assets * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
19.27
|
22.97
|
16.36
|
17.77
|
25.61
|
|
Peer Median
|
14.98
|
2.19
|
1.46
|
2.77
|
--
|
EBIT Margin
17.94
--
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
17.94
|
15.33
|
18.31
|
14.12
|
5.36
|
|
Peer Median
|
--
|
2.93
|
3.78
|
4.14
|
--
|
Net Margin
17.12
Higher than Peers by 8.68
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
17.12
|
12.29
|
10.61
|
7.26
|
3.66
|
|
Peer Median
|
8.44
|
1.96
|
3.27
|
13.99
|
--
|
Cash Profit Margin
17.54
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
17.54
|
12.69
|
11.50
|
8.54
|
3.93
|
|
Peer Median
|
--
|
0.00
|
0.00
|
0.00
|
--
|
Revenue Growth
29.20
--
Year on year growth in net sales
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
29.20
|
111.71
|
18.43
|
-42.54
|
--
|
|
Peer Median
|
--
|
50.75
|
56.32
|
1,43,500.00
|
--
|
EBIT Growth
51.24
--
Year on year growth in operating profit (EBIT)
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
51.24
|
77.20
|
53.55
|
51.42
|
--
|
|
Peer Median
|
--
|
75.04
|
59.55
|
-70.24
|
--
|
Net Profit Growth
81.11
--
Year on year growth in profit after tax
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
81.11
|
145.30
|
73.70
|
14.16
|
--
|
|
Peer Median
|
--
|
39.96
|
-8.68
|
-48.33
|
--
|
EPS Growth
32.67
--
Year on year growth in earnings per share
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
32.67
|
95.03
|
29.68
|
-5.86
|
--
|
|
Peer Median
|
--
|
-21.00
|
--
|
--
|
--
|
Book Value Growth
132.49
--
Year on year growth in book value per share
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
132.49
|
103.28
|
156.66
|
203.73
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.09
Lower than Peers by 0.24
Total debt / Net worth
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
0.09
|
0.16
|
0.19
|
0.62
|
0.61
|
|
Peer Median
|
0.34
|
--
|
0.63
|
--
|
--
|
Short term debt to equity ratio
0.01
--
(Short term borrowings / Net worth)
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
0.01
|
0.04
|
0.11
|
0.29
|
0.61
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
4.71
Higher than Peers by 2.56
Current Assets / Current Liabilities and Provisions
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
4.71
|
5.50
|
3.12
|
1.83
|
0.93
|
|
Peer Median
|
2.15
|
2.47
|
2.33
|
5.05
|
--
|
Quick Ratio
3.21
--
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
3.21
|
2.88
|
1.92
|
1.09
|
0.80
|
|
Peer Median
|
--
|
1.68
|
10.32
|
6.03
|
--
|
Interest Coverage
10.87
Higher than Peers by 5.98
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
10.87
|
18.03
|
8.39
|
9.33
|
70.21
|
|
Peer Median
|
4.89
|
2.66
|
2.65
|
2.05
|
--
|
Operating Efficiency
Debtors to sales
35.20
--
Debtors outstanding / Net Sales * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
35.20
|
16.48
|
38.92
|
23.69
|
6.41
|
|
Peer Median
|
--
|
15.37
|
42.99
|
49.21
|
--
|
Asset Turnover
1.11
--
Sales / Average Total Assets
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
1.11
|
1.86
|
1.53
|
2.44
|
7.00
|
|
Peer Median
|
--
|
1.51
|
1.33
|
0.50
|
--
|
Receivable days
87.52
--
Average Debtors / Sales * 365
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
87.52
|
63.63
|
107.54
|
63.58
|
23.38
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
110.76
--
Average Inventory / Sales * 365
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
110.76
|
79.57
|
83.72
|
39.87
|
4.35
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
43.45
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
43.45
|
14.65
|
42.28
|
33.46
|
12.32
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
154.84
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
154.84
|
128.55
|
148.98
|
70.00
|
15.42
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
8.49
Lower than Peers by 7.21
Current share price divided by earning per share in the last twelve months
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
8.49
|
--
|
--
|
--
|
--
|
|
Peer Median
|
15.70
|
65.30
|
159.13
|
107.97
|
--
|
Price / Book Value
1.55
Lower than Peers by 0.20
Current share price divided by book value per share in the latest financial year
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
1.55
|
--
|
--
|
--
|
--
|
|
Peer Median
|
1.75
|
2.35
|
3.26
|
2.54
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
6.39
Lower than Peers by 1.51
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
6.39
|
1.13
|
1.43
|
2.00
|
0.57
|
|
Peer Median
|
7.90
|
53.35
|
29.43
|
2.43
|
--
|
Market Cap
111
Lower than Peers by 14
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
111
|
--
|
--
|
--
|
--
|
|
Peer Median
|
125
|
30
|
20
|
13
|
--
|
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
